JOHN KIRKWOOD to Gastrointestinal Microbiome
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Gastrointestinal Microbiome.
Connection Strength
0.062
-
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024 Nov 11; 42(11):1898-1918.e12.
Score: 0.035
-
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021 02 05; 371(6529):595-602.
Score: 0.027